BioLineRx Ltd.

BLRX · NASDAQ
Analyze with AI
11/24/2025
6/30/2025
3/31/2025
12/31/2024
Revenue$4,943$304$255$11,749
% Growth1,526%19.2%-97.8%
Cost of Goods Sold-$822$72$34$6,089
Gross Profit$4,121$232$221$5,660
% Margin83.4%76.3%86.7%48.2%
R&D Expenses-$2,565$2,326$1,623$1,865
G&A Expenses$0$209$989$14,055
SG&A Expenses-$1,390$209$989$5,825
Sales & Mktg Exp.-$5,553$0$0-$8,230
Other Operating Expenses$0$0$0$2,396
Operating Expenses-$7,953$2,535$2,612$10,086
Operating Income$0-$2,303-$2,391-$4,426
% Margin0%-757.6%-937.6%-37.7%
Other Income/Exp. Net$756-$1,637$7,518$1,239
Pre-Tax Income$0-$3,940$5,127-$3,187
Tax Expense$0$0$0$0
Net Income-$5,822-$3,940$5,127-$3,187
% Margin-117.8%-1,296.1%2,010.6%-27.1%
EPS-1.47-10.065-0.041
% Growth-47%-1,650.4%259.3%
EPS Diluted-1.47-10.065-0.041
Weighted Avg Shares Out3,9493,94979,85679,856
Weighted Avg Shares Out Dil3,9493,94979,85679,856
Supplemental Information
Interest Income$0$490$294$286
Interest Expense$0$276$420$4,435
Depreciation & Amortization$0$176$165$1,852
EBITDA$0-$3,488$5,712$3,100
% Margin0%-1,147.4%2,240%26.4%
BioLineRx Ltd. (BLRX) Financial Statements & Key Stats | AlphaPilot